Bharat Immunologicals Debt to Equity vs. Current Valuation Fundamental Analysis
Bharat Immunologicals Biologicals Corp Ltd is rated below average in current valuation category among related companies. It is rated third in debt to equity category among related companies . The ratio of Current Valuation to Debt to Equity for Bharat Immunologicals Biologicals Corp Ltd is about 1,725,000,000 Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging barrowing against the capital invested by the owners.
Use alpha and beta coefficients to find investment opportunities after accounting for the riskFind Alpha
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and familiesResearch Equities
Find insiders across different sectors to evaluate their impact on performance and growth of their entitiesResearch Insiders